重组人粒细胞集落刺激因子对新型冠状病毒肺炎伴淋巴细胞减少患者的疗效:一项随机临床试验
该多中心开放标签随机临床试验于2020年2月18日至4月10日在中国3个中心开展,纳入200例确诊新冠肺炎、淋巴细胞计数≤800/μL且无合并症的患者。患者随机接受常规治疗或常规治疗联合rhG-CSF 5 μg/kg皮下注射第0-2天共3剂。主要终点(7分类疾病严重程度评分改善至少1分的时间)两组相似(中位12天 vs 13天;HR 1.28,95%CI 0.95-1.71,P=0.06)。次要终点显示rhG-CSF组进展为ARDS、脓毒症或脓毒性休克的比例更低(2% vs 15%),21天死亡更少(2% vs 10%;HR 0.19,95%CI 0.04-0.88),但作者结论认为这些仅为初步发现,需更大规模研究。
要点
- 在无合并症的新冠肺炎伴淋巴细胞减少(≤800/μL)患者中,rhG-CSF 5 μg/kg皮下注射第0-2天共3剂未显著缩短临床改善时间(中位12天 vs 13天;HR 1.28,95%CI 0.95-1.71,P=0.06)。
- rhG-CSF组进展为ARDS、脓毒症或脓毒性休克的比例为2%,低于常规治疗组的15%(差值-13%,95%CI -21.4%至-5.4%)。
- 21天时rhG-CSF组死亡2例(2%),常规治疗组死亡10例(10%),HR 0.19(95%CI 0.04-0.88)。
- 第5天淋巴细胞计数rhG-CSF组中位1050/μL,高于常规治疗组的620/μL(中位数差值440,95%CI 380-490)。
- 严重不良事件(脓毒症或脓毒性休克、呼吸衰竭、ARDS)rhG-CSF组29例(14.5%),常规治疗组42例(21%)。
适用人群与场景
- 确诊SARS-CoV-2感染(逆转录聚合酶链反应检测阳性)、肺炎、血淋巴细胞计数≤800/μL且无合并症的患者。
- 研究在中国3个中心开展,纳入时间为2020年2月18日至4月10日。
诊断标准与关键阈值
- 主要纳入标准:肺炎,血淋巴细胞计数≤800/μL,无合并症,SARS-CoV-2感染经逆转录聚合酶链反应检测确认。
处置流程与药物剂量
- 干预组:常规治疗联合重组人粒细胞集落刺激因子(rhG-CSF)5 μg/kg皮下注射,第0-2天共3剂。
- 对照组:仅常规治疗。
研究设计与关键结果
- 开放标签、多中心随机临床试验,纳入200例患者,rhG-CSF组100例,常规治疗组100例;男性112例(56%),中位年龄45岁(IQR 40-55岁)。
- 主要终点(随机化至7分类疾病严重程度评分改善至少1分的时间):rhG-CSF组中位12天(IQR 10-16天)vs 常规治疗组中位13天(IQR 11-17天);HR 1.28(95%CI 0.95-1.71;P=0.06)。
- 次要终点:进展为ARDS、脓毒症或脓毒性休克的比例rhG-CSF组2% vs 常规治疗组15%(差值-13%,95%CI -21.4%至-5.4%)。
- 21天死亡:rhG-CSF组2例(2%)vs 常规治疗组10例(10%);HR 0.19(95%CI 0.04-0.88)。
- 第5天淋巴细胞计数:rhG-CSF组中位1050/μL vs 常规治疗组中位620/μL;中位数差值Hodges-Lehmann估计440(95%CI 380-490)。
- 严重不良事件(脓毒症或脓毒性休克、呼吸衰竭、ARDS):rhG-CSF组29例(14.5%)vs 常规治疗组42例(21%)。
证据类型、等级与局限
- 证据类型:开放标签、多中心随机临床试验。
- 作者结论:初步发现显示rhG-CSF未加速临床改善,但可能减少危重症或死亡的发生;需开展纳入更广泛新冠肺炎患者群体的更大规模研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于无合并症的新冠肺炎伴淋巴细胞减少患者,rhG-CSF治疗未加速临床改善,但可能减少危重症或死亡的发生。
- 作者建议,需开展纳入更广泛患者群体的更大规模研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Lymphopenia is common and correlates with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
OBJECTIVE: To determine whether a therapy that increases peripheral blood leukocyte and lymphocyte cell counts leads to clinical improvement in patients with COVID-19.
DESIGN, SETTING AND PARTICIPANTS: Between February 18 and April 10, 2020, we conducted an open-label, multicenter, randomized clinical trial at 3 participating centers in China. The main eligibility criteria were pneumonia, a blood lymphocyte cell count of 800 per μL (to convert to ×109/L, multiply by 0.001) or lower, and no comorbidities. Severe acute respiratory syndrome coronavirus 2 infection was confirmed with reverse-transcription polymerase chain reaction testing.
EXPOSURES: Usual care alone, or usual care plus 3 doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2).
MAIN OUTCOMES AND MEASURES: The primary end point was the time from randomization to improvement of at least 1 point on a 7-category disease severity score.
RESULTS: Of 200 participants, 112 (56%) were men and the median (interquartile range [IQR]) age was 45 (40-55) years. There was random assignment of 100 patients (50%) to the rhG-CSF group and 100 (50%) to the usual care group. Time to clinical improvement was similar between groups (rhG-CSF group median of 12 days (IQR, 10-16 days) vs usual care group median of 13 days (IQR, 11-17 days); hazard ratio, 1.28; 95% CI, 0.95-1.71; P = .06). For secondary end points, the proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock was lower in the rhG-CSF group (rhG-CSF group, 2% vs usual care group, 15%; difference, -13%; 95%CI, -21.4% to -5.4%). At 21 days, 2 patients (2%) had died in the rhG-CSF group compared with 10 patients (10%) in the usual care group (hazard ratio, 0.19; 95%CI, 0.04-0.88). At day 5, the lymphocyte cell count was higher in the rhG-CSF group (rhG-CSF group median of 1050/μL vs usual care group median of 620/μL; Hodges-Lehmann estimate of the difference in medians, 440; 95% CI, 380-490). Serious adverse events, such as sepsis or septic shock, respiratory failure, and acute respiratory distress syndrome, occurred in 29 patients (14.5%) in the rhG-CSF group and 42 patients (21%) in the usual care group.
CONCLUSION AND RELEVANCE: In preliminary findings from a randomized clinical trial, rhG-CSF treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients developing critical illness or dying may have been reduced. Larger studies that include a broader range of patients with COVID-19 should be conducted.
TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2000030007.
参考来源
- Cheng LL, Guan WJ, Duan CY, et al. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med. 2021. PMID: 32910179. doi:10.1001/jamainternmed.2020.5503
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。